menu
    • menu
    [{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Miravo Healthcare \/ Orion Corporation"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sumatriptan","moa":"5-HT1B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Nuvo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvo Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Nuvo Pharmaceuticals \/ Orion Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals for Sumatriptan

    Menu

    Sumatriptan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nuvo Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Nuvo Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Orion Corporation

                            Deal Size : $0.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets

                            Details : The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U....

                            Brand Name : Suvexx

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Orion Corporation

                            Deal Size : $0.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : $25.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

                            Details : Through the acquisition, Tonix gets two FDA approved products including, Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), indicated for the treatment of acute migraine in adults.

                            Brand Name : Zembrace SymTouch

                            Molecule Type : Small molecule

                            Upfront Cash : $22.0 million

                            July 03, 2023

                            Lead Product(s) : Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : $25.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : $25.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upshe...

                            Details : The acquisition of two currently-marketed products Zembrace SymTouch (sumatriptan succinate injection) and Tosymra (sumatriptan nasal spray), complement Tonix’s current intranasal clinical development program of TNX-1900 for migraine prevention.

                            Brand Name : Zembrace SymTouch

                            Molecule Type : Small molecule

                            Upfront Cash : $22.0 million

                            June 26, 2023

                            Lead Product(s) : Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : $25.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cipla

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cipla

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cipla Receives Final Approvl for Generic Version of GlaxoSmithKline’s IMITREX®

                            Details : Cipla’s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex® Nasal Spray.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 02, 2021

                            Lead Product(s) : Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Miravo Healthcare

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Miravo Healthcare

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Miravo Healthcare Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select ...

                            Details : Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estoni...

                            Brand Name : Suvexx

                            Molecule Type : Small molecule

                            Upfront Cash : $2.0 million

                            December 21, 2020

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth